

Glycoform Limited  
Unit 44C  
Milton Park  
Abingdon  
Oxford  
OX14 4RU



April 2006

Glycoform announce that Michael Short has been appointed CEO

Glycoform has today announced that Michael Short has been appointed CEO of Glycoform with immediate effect. Glycoform is an established glycoscience company based in Milton Park in Oxfordshire.

Glycoform leads in the improvement of biological therapeutics through targeted glycosylation. The company's most advanced product candidates, a glycoprotein hormone and an enzyme, are in development with preclinical work anticipated to start in late 2006. Glycoform's approach has the potential to significantly improve upon existing proven biological therapeutics and this market will be worth in excess of \$50 billion by 2010. Glycoform's technology is equally applicable to products in preclinical and clinical development today.

Michael has previously held senior general management and business development positions both in the UK and abroad, working internationally for companies such as Baxter and PathoGenesis (now Chiron). He has broad experience in the biotechnology arena in many consulting roles and has founded biotechnology companies, the most recent of which is RioTech Pharmaceuticals Ltd where he was also CEO.

Speaking for the Board, Chairman Dr Mario Polywka stated "Glycoform and its shareholders are delighted to welcome Michael Short as CEO. Michael's recruitment means Glycoform, with its established laboratories and world-renowned science and staff, is poised to become a major player in the field of glycoscience and drug development.

On his appointment Michael said "I am excited to be joining a successful and established team, with two highly commercial programmes using our proprietary chemistry", he continued "the prospects for rapid and significant advance in Glycoform's lead programmes, with committed international investors, makes Glycoform one of the leading biotech opportunities in the UK."

For further information:  
Glycoform Ltd: +44 (0) 1235 820 463  
Michael Short, Chief Executive Officer

-ENDS-

#### About Glycoform

Glycoform Ltd is a biotechnology company developing next generation glycoproteins. Glycoform uses its capabilities in the design and synthesis of homogeneous sugars (oligosaccharides) combined with site directed conjugation techniques to add these sugars to proteins to deliver optimised and uniform next generation glycoprotein therapeutics. The flexibility of the approach means that all proteins from any expression system may now be glycosylated with both naturally occurring and novel sugar structures. The Company's most advanced development candidate is GLY510, a hormone treatment for anaemia. Glycoform was founded in 2002 and is based near Oxford in the UK.